相关实验视频

Updated: Jul 9, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

在Hutchinson-Gilford前列腺综合征的临界大动脉狭窄的干预

Leslie B Gordon^1,2,3, Sammy Basso^3,4,5,6, Justine Maestranzi³

¹Division of Genetics, Department of Pediatrics, Hasbro Children's Hospital and Warren Alpert Medical School of Brown University, Providence, RI, United States.

Frontiers in cardiovascular medicine

|May 10, 2024

概括

哈森-吉尔福德进展症候群 (HGPS) 患者面临新的心脏风险. 像TAVR和AAC这样的专家干预措施显示出改善这种罕见的衰老疾病的寿命和生活质量的希望.

科学领域:

心血管医学心血管医学
遗传学遗传学是一个
罕见疾病罕见疾病

背景情况:

哈森-吉尔福德进展症候群 (HGPS) 是一种罕见的遗传疾病,导致快速过早衰老和过早死亡,主要是动脉样硬化.
洛纳法尼布治疗延长了寿命,但揭示了性大动脉狭窄症 (AS) 作为心脏死亡的关键新兴风险.
由于疾病特异性并发症,HGPS患者在心脏干预方面存在独特的挑战.

研究的目的:

识别和评估在HGPS患者中成功治疗关键大动脉狭窄症的策略.
评估这种极为罕见的人群中新型心脏干预的可行性和结果.
为未来的临床管理提供信息,并改善HGPS患者的健康和寿命.

主要方法:

召集了一个国际专家小组,讨论HGPS临床病理和治疗策略.
通过对四个代表性的HGPS案例进行深入分析,评估了候选程序.
评估修改过导管大动脉置换 (TAVR) 和阿皮科大动脉管 (AAC) 放置作为潜在的干预措施.

主要成果:

修改的TAVR和AAC配置被确定为高风险但可行的选择,用于HGPS中的关键AS.
接受这些干预的四分之三的患者经历了成功的结果.
一名患者在术前死亡,这强调了干预时间和风险分层的重要性.

结论:

突破性心脏干预AS在HGPS患者提供了显著改善生活质量和延长寿命的潜力.
扩大全球专业知识和信息共享对于优化这种超罕见疾病的治疗成功至关重要.
这些干预措施可能从根本上改变对HGPS晚期病程的临床观点.

关键词:

衰老的衰老衰老的衰老大动脉狭窄症 (大动脉狭窄)顶动脉 - 大动脉管道动脉样硬化动脉样硬化孕病是什么意思孕病是什么意思通过导管更换大动脉门.

更多相关视频

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position

Published on: April 1, 2022

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Mitral Stenosis III: Medical Management

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Huntington Disease l: Introduction

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...